← Trials/Trial dossier/NCT06000891
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
A Randomised, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 Administered in Subjects With Overweight or Obesity
Lead sponsor
Assets
Dapiglutide / GLP-1 / incretin class catch-all
Listed sites
1
Recruiting sites
—
Enrollment
84
actual
Study population
Obesity / overweight
Key I/E criterion
•BMI 27-39.9
Primary endpoint
•Treatment-emergent AEs (any)
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
Exclusion criteria
Serum creatinine above UNL+10% or normalised estimated glomerular filtration rate (eGFR) below 60.0 l/min/1.73m2, as defined by CKD-EPI.
Endpoints (11)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Weight & body composition
2 endpointsAbsolute change in body weight
Time frame:Day 1 and Day 92 in Part 1. Day 1 and Day 197 in Part 2.
Body weight, absolute change (kg)
change from baseline, improvement
Percent change in body weight
Time frame:Day 1 and Day 92 in Part 1. Day 1 and Day 197 in Part 2.
Body weight, % change
percent change from baseline, improvement
Safety / tolerability / PK
9 endpointsIncidence of treatment emergent adverse events (TEAEs)
Time frame:Day 1 to Day 127 in Part 1. Day 1 to Day 232 in Part 2
Treatment-emergent AEs (any)
event count, event
Pharmacokinetics endpoints related to ZP7570 exposure
Time frame:Area under the drug concentration curve from baseline (Day 1) to 18 weeks (Day 127) in Part 1 and to 33 weeks (Day 232) in Part 2.
AUC₀–∞
concentration, descriptive
Pharmacokinetics endpoints related to ZP7570 exposure
Time frame:Maximum drug concentration (Cmax) from baseline (Day 1) to 18 weeks (Day 127) in Part 1 and to 33 weeks (Day 232) in Part 2.
Cmax
concentration, descriptive
Pharmacokinetics endpoints related to ZP7570 exposure
Time frame:Time to maximum plasma concentration from baseline (Day 1) to 18 weeks (Day 127) in Part 1 and to 33 weeks (Day 232) in Part 2.
Tmax
descriptive
Pharmacokinetics endpoints related to ZP7570 exposure
Time frame:Elimination rate constant from baseline baseline (Day 1) to 18 weeks (Day 127) in Part 1 and to 33 weeks (Day 232) in Part 2.
descriptive
Pharmacokinetics endpoints related to ZP7570 exposure
Time frame:Elimination half-life from baseline baseline (Day 1) to 18 weeks (Day 127) in Part 1 and to 33 weeks (Day 232) in Part 2.
Half-life
descriptive
Pharmacokinetics endpoints related to ZP7570 exposure
Time frame:Apparent volume of distribution from baseline baseline (Day 1) to 18 weeks (Day 127) in Part 1 and to 33 weeks (Day 232) in Part 2.
descriptive
Pharmacokinetics endpoints related to ZP7570 exposure
Time frame:Apparent total clearance of the drug from plasma from baseline baseline (Day 1) to 18 weeks (Day 127) in Part 1 and to 33 weeks (Day 232) in Part 2.)
descriptive
Pharmacokinetics endpoints related to ZP7570 exposure
Time frame:Trough concentration measured from baseline baseline (Day 1) to 18 weeks (Day 127) in Part 1 and to 33 weeks (Day 232) in Part 2.
Plasma concentration (steady state)
concentration, descriptive
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.